# Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

> **NCT03650114** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 1882 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** Ofatumumab
- **BIOLOGICAL:** Tetanus toxoid (TT) containing vaccine (Td, Tdap)
- **BIOLOGICAL:** 13-valent pneumococcal conjugate vaccine (13-PCV)
- **BIOLOGICAL:** 23-valent pneumococcal polysaccharide vaccine (23-PPV)
- **BIOLOGICAL:** Seasonal Quadrivalent influenza vaccine
- **BIOLOGICAL:** Keyhole limpet hemocyanin (KLH) neo-antigen

## Key facts

- **NCT ID:** NCT03650114
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-12-28
- **Primary completion:** 2028-09-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 1882 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03650114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03650114, "Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT03650114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*